Production assistance for cellular therapies (pact)- cell processing facilities

Ended Awarded Last action

Contract number
HHSN268201600012I
Awardee
Awarding agency
Task orders
11 $5,254,284 obligated

Award facts

Opportunity
  • NHLBIECBHB201609JB Solicitation number
Combined order value
  • $5,254,284 Current, with exercised options
  • $5,784,291 Potential, with all options
Last date to order 100% complete
IDV ceiling 12% used
$45,630,651.00
Award type
Multiple award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
10 offers Negotiated Proposal / Quote
Pricing
Order Dependent (IDV only)

Award details come from SAM.gov/FPDS.

About this IDV

The Production Assistance for Cellular Therapies (PACT) - Cell Processing Facilities indefinite delivery contract, awarded by the National Heart, Lung and Blood Institute (NHLBI) to the University of Miami Office of Research Administration - School of Medicine Division on July 29, 2016, provides a multiple-award vehicle with a ceiling value of $45.6 million and ultimate completion date of June 30, 2022. The contract was awarded without set-aside designation under full and open competition and is performed at the University of Miami's facilities in South Miami, Florida. This indefinite delivery contract structure allows the NHLBI to issue task orders for specialized cell manufacturing and process development services that support the agency's regenerative medicine and cellular therapy research initiatives. The contract does not specify a set-aside category, reflecting its competitive procurement approach.

The task orders issued against this PACT-CPF master contract demonstrate the breadth of cellular therapy manufacturing services delivered by the University of Miami, including induced pluripotent stem cell (iPSC) line production, cardiac progenitor cell scale-up operations, iPSC-derived cardiomyocyte bank manufacturing, cryopreservation technical studies, mesenchymal stromal cell (MSC) processing from Wharton's jelly for bronchopulmonary dysplasia research, MSC-derived exosome manufacturing scale-up, fibroblast master and working cell bank production, and product quality improvement initiatives. Individual delivery orders range from approximately $185,000 to $1.18 million, with cost-no-fee and firm-fixed-price pricing structures. These task orders, awarded between August 2016 and December 2019, support the NHLBI's mission to advance cellular therapeutic development through access to specialized cell processing facilities and expertise, enabling rigorous manufacturing and testing of cell-based therapies for cardiovascular and pulmonary diseases.

Task orders

Task order Ordering agency Obligated Awarded
Production assistance for cellular therapies (pact)- cell processing facilities cell manufacturing and process… 75N92020F00001 National Heart Lung and Blood Institute (NIH) $1,016,452
Production assistance for cellular therapies (pact)- cell processing facilities cell manufacturing and process… 75N92019F00075 National Heart Lung and Blood Institute (NIH) $154,494
Production assistance for cellular therapies (pact)- cell processing facilities cell manufacturing and process… 75N92019F00074 National Heart Lung and Blood Institute (NIH) $570,297
Production assistance for cellular therapies (pact)- cell processing facilities cell manufacturing and process… 75N92019F00037 National Heart Lung and Blood Institute (NIH) $208,810
Production assistance for cellular therapies (pact)- cell processing facilities cell manufacturing and process… 75N92018F00007 National Heart Lung and Blood Institute (NIH) $184,996
PCT0012-01: wharton's jelly-derived mscs for BPD 75N92018F00006 National Heart Lung and Blood Institute (NIH) $758,015
PCT0013-01: scale up processes for MSC derived exosomes 75N92018F00005 National Heart Lung and Blood Institute (NIH) $305,762
PCT0004-02: improving CSC product quality HHSN26800004 National Heart Lung and Blood Institute (NIH) $303,060
Production of fibroblast master and working cell banks this task shall require establishment of all necessary… HHSN26800003 National Heart Lung and Blood Institute (NIH) $723,091
Production assistance for cellular therapies (pact)- cell processing facilities HHSN26800002 National Heart Lung and Blood Institute (NIH) $378,425
Production assistance for cellular therapies (pact)- cell processing facilities HHSN26800001 National Heart Lung and Blood Institute (NIH) $650,882
Show all 11

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00003 $0
Supplemental Agreement for work within scope P00002 $0
Change Order 1 · Purpose: to correct typographical errors in article b.5. Option prices, and article f.3. Deliveries, item b., and add article i.4. Additional far contract… $0
Original award $0

Quick answers

Who was awarded contract HHSN268201600012I?

HHSN268201600012I was awarded to University Of Miami by National Heart Lung and Blood Institute (National Institutes of Health) on July 29, 2016.

How much is contract HHSN268201600012I worth?

Orders under HHSN268201600012I have obligated $5,254,284. Their combined potential value, with all options, is $5,784,291. HHSN268201600012I's own ceiling is $45,630,651.

How many orders have been placed under contract HHSN268201600012I?

11 orders have been placed under HHSN268201600012I, the latest on December 10, 2019.

Who can order from contract HHSN268201600012I?

HHSN268201600012I is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract HHSN268201600012I part of a contract vehicle?

Yes. HHSN268201600012I is part of Production Assistance for Cellular Therapies - Cell Processing Facilities (PACT-CPF).

Was contract HHSN268201600012I competed?

The government received 10 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV